Global Congestive Heart Failure Drugs Market 2015-2019

Description:
Congestive heart failure is a serious and complex condition in which the heart muscles are either damaged or have to work too hard. Although the heart beats, the damaged heart muscles are too weak to pump sufficient oxygen-rich blood to and from the body. ACE inhibitors/ARB antagonists, beta-adrenergic receptor blocking agents, diuretics, and inotropic drugs are the medications available for the treatment of congestive heart failure.

The analysts forecast the Global Congestive Heart Failure Drugs market to grow at a CAGR of 9.47 percent over the period 2014-2019.

Covered in this Report
This report covers the present scenario and the growth prospects of the Global Congestive Heart Failure Drugs market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of approved drugs and generics used in the treatment of congestive heart failure that are available in the market. The Global Congestive Heart Failure Drugs market can be divided into four segments: ACE Inhibitors/ARB Antagonists, Beta-adrenergic Receptor Blocking Agents, Diuretics, and Inotropic Drugs/Vasodilators.

The report, the Global Congestive Heart Failure Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Congestive Heart Failure Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions
- Americas
- APAC
- EMEA

Key Vendors
- AstraZeneca
- Bristol-Myers Squibb
- GSK
- Merck & Co.
- Mylan
- Novartis
- Pfizer
- Sanofi
- Valeant Pharmaceuticals

Other Prominent Vendors
- Bayer
- Bioheart
- Boehringer Inhelheim
- Takeda Pharmaceutical
- Teva Pharmaceutical Industries

Market Drivers
- Increase in Aging Population
- For a full, detailed list, view our report

Market Challenges
- Weak Pipeline
- For a full, detailed list, view our report

Market Trends
- Increase in Awareness
- For a full, detailed list, view our report

Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key Market Trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
18.9 Valeant Pharmaceuticals International
18.9.1 Key Facts
18.9.2 Business Overview
18.9.3 Business Segmentation by Revenue 2013
18.9.4 Business Segmentation by Revenue 2012 and 2013
18.9.5 Sales by Geography
18.9.6 Business Strategy
18.9.7 Key Developments
18.9.8 SWOT Analysis
19. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Congestive Heart Failure Drugs Market 2014-2019 (US$ billion)
Exhibit 3: Global Congestive Heart Failure Drugs Market Segmentation by Therapeutic Class
Exhibit 4: Congestive Heart Failure: Clinical Developmental Pipeline
Exhibit 5: Global Congestive Heart Failure Drugs Market by Geographical Segmentation 2014
Exhibit 6: Congestive Heart Failure Drugs market in Americas 2014-2019 (US$ billion)
Exhibit 7: Congestive Heart Failure Drugs market in Europe 2014-2019 (US$ billion)
Exhibit 8: Congestive Heart Failure Drugs market in Asia 2014-2019 (US$ billion)
Exhibit 9: Congestive Heart Failure Drugs Market in ROW 2014-2019 (US$ billion)
Exhibit 10: Global Congestive Heart Failure Drugs Market by Geographical Segmentation 2014-2019 (in Percent)
Exhibit 11: Global Congestive Heart Failure Drugs Market by Geographical Segmentation 2014-2019 (in Revenue)
Exhibit 12: Estimated Prevalence of Congestive Heart Failure in Different Age-group (years) in the US
Exhibit 13: Age-specific Male Incidence Rates (per 1000 man years) in Congestive Heart Failure
Exhibit 14: Age-specific Female Incidence Rates (per 1000 woman-years) in Congestive Heart Failure
Exhibit 15: AstraZeneca Year on Year Sales Comparison 2010-2013 (US$ billion)
Exhibit 16: GSK Year on Year Sales Comparison 2010-2013 (US$ billion)
Exhibit 17: GSK’s Total Global Sales of Medicines by Therapeutic Classes 2013 (percentage)
Exhibit 18: GSK Coreg Year on Year Sales Comparison 2010-2013 (US$ billion)
Exhibit 19: Merck & Co. Year on Year Sales Comparison 2010-2013 (US$ billion)
Exhibit 20: Mylan Year on Year Sales Comparison 2010-2013 (US$ billion)
Exhibit 21: Novartis Diovan Year on Year Sales Comparison 2010-2013 (US$ billion)
Exhibit 22: Novartis Year on Year Sales Comparison 2010-2013 (US$ billion)
Exhibit 23: Pfizer Year on Year Sales Comparison 2010-2013 (US$ billion)
Exhibit 24: Sanofi Year on Year Sales Comparison 2010-2013 (US$ billion)
Exhibit 25: Valeant Pharmaceuticals Year on Year Sales Comparison 2010-2013 (US$ billion)
Exhibit 26: Valeant Pharmaceuticals Revenue Breakdown by Product Segments
Exhibit 27: AstraZeneca plc: Business Segmentation by Revenue 2013
Exhibit 28: AstraZeneca plc: Business Segmentation by Revenue 2011-2013 (US$ billion)
Exhibit 29: AstraZeneca plc: Sales by Geography 2013
Exhibit 30: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
Exhibit 31: Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
Exhibit 32: GlaxoSmithKline: Business Segmentation 2013
Exhibit 33: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 34: GlaxoSmithKline: Sales by Geography 2013
Exhibit 35: GlaxoSmithKline: Pipeline Products 2013
Exhibit 36: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 37: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 38: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 39: Global Congestive Heart Failure Drugs Market: Business Segmentation by Revenue 2013
Exhibit 40: Global Congestive Heart Failure Drugs Market: Business Segmentation by Revenue 2011-2013 (US$ billion)
Exhibit 41: Global Congestive Heart Failure Drugs Market: Geographical Segmentation by Revenue 2013
Exhibit 42: Novartis AG: Business Segmentation
Exhibit 43: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 44: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 45: Novartis AG: Revenue by Geographical Segmentation 2013
Exhibit 46: Pfizer: Business Segmentation by Revenue 2013
Exhibit 47: Pfizer: Business Segmentation by Revenue 2012 and 2013
Exhibit 48: Pfizer: Geographical Segmentation by Revenue 2013
Exhibit 49: Sanofi SA: Business Segmentation
Exhibit 50: Sanofi SA: Revenue by Business Segmentation 2013
Exhibit 51: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 52: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
Exhibit 53: Valeant Pharmaceuticals International: Business Segmentation by Revenue 2013
Exhibit 54: Valeant Pharmaceuticals International: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 55: Valeant Pharmaceuticals International: Sales by Geography 2013

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3085040/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,  
Guinness Centre,  
Taylors Lane,  
Dublin 8,  
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Congestive Heart Failure Drugs Market 2015-2019
Web Address: http://www.researchandmarkets.com/reports/3085040/
Office Code: SCPL1HJN

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 3000</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users:</td>
<td>USD 3500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 4500</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 10000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof
First Name: ___________________________________________  Last Name: ___________________________________________
Email Address: * ___________________________________________
Job Title: ___________________________________________
Organisation: ___________________________________________
Address: ___________________________________________
City: ___________________________________________
Postal / Zip Code: ___________________________________________
Country: ___________________________________________
Phone Number: ___________________________________________
Fax Number: ___________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World